PFS was significantly improved in the docetaxel plus nintedanib group compared with the docetaxel plus placebo group ( median @ months -LSB- @ % CI @-@ -RSB- vs @ months -LSB- @-@ -RSB- ; hazard ratio -LSB- HR -RSB- @ -LSB- @ % CI @-@ -RSB- , p = @ ) .